Skip to main content
. 2013 Aug 14;20(1):58. doi: 10.1186/1423-0127-20-58

Figure 2.

Figure 2

Outcome of patients with CN-AML according to BDH2 expression levels and FLT3-ITD mutation status. In 85 patients receiving intensive induction chemotherapy, we analyzed A) overall survival; B) leukemia-free survival between 2 different BDH2 expression groups; and C) overall survival; D) leukemia-free survival between groups differentiated by BDH2 expression level, combined with the FLT3-ITD mutation status.